Latest Breaking News On - Nguengang wakap - Page 1 : comparemela.com

The substantial investments in human genetics and genomics made over the past three decades were anticipated to result in many innovative therapies. Here we investigate the extent to which these expectations have been met, excluding cancer treatments. In our search, we identified 40 germline genetic observations that led directly to new targets and subsequently to novel approved therapies for 36 rare and 4 common conditions. The median time between genetic target discovery and drug approval was 25 years. Most of the genetically driven therapies for rare diseases compensate for disease-causing loss-of-function mutations. The therapies approved for common conditions are all inhibitors designed to pharmacologically mimic the natural, disease-protective effects of rare loss-of-function variants. Large biobank-based genetic studies have the power to identify and validate a large number of new drug targets. Genetics can also assist in the clinical development phase of drugs—for example

San franciscoUnited statesSouthwest finlandVan goorLopes alvesDavey smithNguengang wakapFinasteride male pattern hair loss study groupFinasteride study groupPrecision medicine initiative all of usHealth drugEstonian genome centerAmerican heart associationCollaborative groupHuman servicesUs department of health